



## NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2025 (UNAUDITED)

*Company announcement, Helsinki, August 15, 2025 at 9 am (EEST)*

### NEXSTIM ACCELERATED GROWTH AND IMPROVED PROFITABILITY IN THE FIRST HALF OF THE YEAR

The figures in parentheses refer to the previous year's comparative period, unless otherwise stated.

#### January–June 2025 in brief

- The company's net sales were EUR 4.5 million (3.2), with an increase of 41.8 %
- Net sales growth adjusted for currency exchange rates was 42.5 %
- System sales were EUR 2.2 million (1.2), with an increase of 79.7 %. Recurring net sales accounted for EUR 2.1 million (1.9), with an increase of 7.7 %. Licensing accounted for EUR 0.2 million (0.0).
- The net sales of the Diagnostics Business were EUR 2.5 million (1.5) with an increase of 65.3 %
- The net sales of the Therapy Business were EUR 1.4 million (1.6) with a decrease of 8.4 %
- The net sales of the Research and Neuroscience Business were EUR 0.6 million (0.1) with an increase of 565.7 %.
- EBITDA was EUR 0.2 million (-0.5)
- The operating result was EUR -0.2 million (-0.9)
- The result for the period was EUR -0.3 million (-0.9)
- The company signed an exclusivity agreement with Sinaptica Therapeutics, Inc. as part of a planned collaboration in the treatment of Alzheimer's disease. The agreed exclusive rights are conditional on payments totaling EUR 1.5 million to be made to Nexstim in multiple installments during 2025, of which EUR 0.2 million was recognized as revenue during the review period.

#### Business overview

Nexstim is a Finnish medical technology company operating in international markets. Its proprietary navigated Transcranial Magnetic Stimulation (nTMS) technology allows for personalized treatment and diagnostics for patients with challenging brain diseases and disorders. Nexstim provides solutions for non-invasive brain stimulation through diagnostic and therapy applications.

#### Key performance indicators

EUR thousand	1-6/2025 6 months	1-6/2024 6 months	Change, %	1-12/2024 12 months
Net sales	4,506.2	3,176.9	41.8 %	8,735.4
Gross margin	3,633.8	2,603.0	39.6 %	6,901.4
Gross margin, %	80.6 %	81.9 %	-	79.0 %
Adjusted comparable gross margin	3,433.8	2,603.0	31.9 %	6,901.4
Adjusted comparable gross margin, %	79.7 %	81.9 %	-	79.0 %
Personnel expenses	-2,591.7	-2,282.1	13.6 %	-4,784.5
Other operating expenses	-1,667.6	-1,562.6	6.7 %	-3,347.0
EBITDA	240.6	-466.5	-	321.9
Operating result	-246.4	-864.2	-71.5 %	-535.4
Profit/loss for the period	-338.8	-948.1	-64.3 %	-892.3
Earnings per share	-0.05	-0.14	-66.3 %	-0.13
Diluted earnings per share (EUR)	-0.04	-0.12	-69.6 %	-0.11
Cash flow from operating activities	314.6	699.6	-55.0 %	1,881.0

Cash in hand and at bank	2,662.7	3,032.1	-12.2 %	3,864.4
Total equity	3,179.3	1,867.7	70.2 %	3,699.9
Equity ratio (%)	31.9 %	28.7 %	-	31.2 %

## Future outlook for year 2025

The company expects its net sales to grow and operating result to improve.

## CEO Mikko Karvinen comments on the development during the period:

Nexstim continued its positive trend in terms of net sales growth and improved results during the first half of 2025. In H1 2025, we achieved total net sales of EUR 4.5 (3.2) million, representing growth of 41.8%. Gross margin increased by more than EUR 1 million from the comparable period last year to EUR 3.6 (2.6) million, which is a result of the favorable development of our sales volumes and prices. The increased customs duties in the United States did not have a significant impact on the results for the first half of 2025, and we have sought to minimize the potential impact of customs duties on future periods by taking them into account in new system sales offers. We were particularly pleased with the positive development of EBITDA during the first half of the year. EBITDA was EUR 0.2 (-0.5) million and was positively record-breaking for two consecutive half-years. The operating result for the first half of the year also showed improvement in the right direction, at EUR -0.2 (-0.9) million, with a result for the review period of EUR -0.3 (-0.9) million. The result was improved by a non-recurring item of EUR 0.2 million, which was the first installment of the license fee for the exclusivity agreement with Sinaptica. I thank Nexstim's customers, personnel, partners, and investors for the continuation of this positive development.

In line with the main objective of Nexstim's 2025–2028 strategy, we have focused on profitable net sales growth, and our sales forecast for full year 2025 looks promising. This growth is now supported by our global distributor partner network, which was strengthened at the end of last year by the Brainlab cooperation agreement. We are now looking to take immediate advantage of this, particularly in the marketing and sales of diagnostics systems in the United States and Europe. In early 2025, we developed and trained our partner network for the Diagnostics business in close cooperation with Brainlab. This will enable us to effectively and comprehensively deliver our sales and marketing message to as many markets as possible among Brainlab's thousands of existing customers. In addition to this collaboration, Nexstim's direct sales and marketing still have significant opportunities for developing the Therapy business, research and neuroscience customers, and the clinic partner network. We aim to continue leveraging our expert and efficient global teams to ensure positive profitability development. This was reflected in the moderate 11 percent growth in operating expenses in early 2025, enabling a simultaneous 40 percent increase in gross margin.

## Business update

We have continued to grow our Diagnostics (NBS, Navigated Brain Stimulation) and Therapy (NBT®, Navigated Brain Therapy and NBS 6) businesses through the sale of new systems in our key markets in the US and Europe. Our growing installed base generates a steady stream of net sales which increases the stability and predictability of our operations.

The Diagnostics business grew by 65.3% during the first half of 2025, with net sales of EUR 2.5 (1.5) million. We delivered a total of seven new diagnostic systems during H1 2025. To date, we have sold more than 250 diagnostic systems to research universities and leading hospitals around the world. We are pleased that more of our customers want to use Nexstim system for both diagnostic and therapeutic purposes. The NBS System 5 configuration, NBS 5+, has enabled the use of diagnostic and therapeutic applications in the same system. This offering means that all FDA 510(k) indications are available in the same system on the US market. Most of the diagnostic systems delivered in early 2025 have both diagnostic and therapeutic applications. We consider combination systems to be a clear competitive advantage and aim to launch the latest generation of NBS 6 combination systems in key markets during the second half of 2025, following regulatory approvals.

Net sales from the therapy business decreased by 8.4% during the first half of 2025 and amounted to EUR 1.4 (1.6) million. The decline was mainly due to a decrease in system sales in the Therapy business, which fell by 37.0% compared



to the same period last year. During H1 2025, we delivered one purely therapeutic system to Europe and the rest of the world. This development was mainly since most of the therapy applications were delivered in connection with Diagnostics and Research and Neuroscience system. At the end of June 2025, there were a total of 116 Nexstim systems with therapy applications installed worldwide (43 in the United States and 73 in Europe and the rest of the world) for the treatment of depression and chronic neuropathic pain. This number includes both NBT<sup>®</sup> and NBS 6 systems as well as NBS systems with optional NBT add-on software installed.

With the new strategy period, we now also report separately the net sales of the Research and Neuroscience business, which grew by as much as 565.7% during the first half of 2025, amounting to EUR 0.6 (0.1) million. This rapid growth was due to the sale of two research systems and a EUR 0.2 million license fee from Sinaptica's exclusive agreement.

In addition to the above-mentioned system already delivered, we had an open order backlog of eight systems at the end of June 2025.

In June 2024, we announced disagreements regarding the licensing of our technology to the US medical technology company Magnus Medical, Inc. Nexstim received additional information from them regarding the launch of their first commercial product, which, based on additional analysis conducted by the Company and an external party, led to a disagreement regarding the use of the licensed technology. Nexstim continues to gather additional information regarding Magnus Medical's commercial product and is planning further measures to defend its financial interests and intellectual property rights in accordance with the long-term agreement. The Company does not currently expect to receive any royalty income from Magnus Medical during 2025 in its business forecasts. Nexstim is not currently providing an estimate of the total value of the royalty period or financial expectations due to ongoing discussions regarding the disagreements.

Nexstim's cash reserves totaled EUR 2.7 (3.0) million on June 30, 2025, and cash flow from operations for the first half of the year was EUR 0.3 (0.7) million.

### ***Strategic focus remains on growth and profitability***

In line with our strategy for 2025–2028, Nexstim will continue to enable individualized and effective treatment and diagnostics for patients with severe brain diseases and disorders. The company's first strategic objective for 2025 is to continue profitable net sales growth and improve the operating result for the financial year. The growth and profitability of our Diagnostics and Therapy businesses play a key role in our efforts to minimize our future capital requirements on our journey towards sustained profitability. We also want to continue to highlight Research and Neuroscience as well as our clinic partners as special strategic customer groups as we progress with new features, business models, and indications for our future systems. The importance of partnerships is likely to increase in the future in the Therapy business as well, as we leverage our unique expertise and technology in emerging treatment areas.

Our second strategic objective for 2025 is to successfully support the long-term collaboration between Nexstim and Brainlab and to expand our network of other partners and clinics, primarily in the United States. I strongly believe that combining Nexstim's technological expertise and first-class services with Brainlab's innovative products, which have significant business growth potential and are well suited to Nexstim's offering and global customer base of leading hospitals, will create maximum value for patients, neurosurgeons, hospitals, and shareholders. Outside of Brainlab's exclusive rights, Nexstim will continue to independently develop, market, and sell its products and services in all markets for current and future neuroscience research solutions and therapeutic applications. This includes all neuromodulation treatments that are not administered in conjunction with neurosurgical intervention using non-invasive transcranial magnetic stimulation. Nexstim's own sales organization, in collaboration with other distributors and business partners, will continue to work in these areas. The parties have also agreed on certain gross margin targets for payments that Nexstim will receive from the sale of its products (including maintenance agreements) in Brainlab's business area. The gross margin target set for 2025 is EUR 4 million. The EUR 2 million portion of the gross margin target allocated to the first half of 2025 was not yet fully achieved, and a gross profit insurance payment of EUR 0.1 million was recognized as part of the Diagnostics business's net sales for the period.

With the expansion of the network of partner clinics, Nexstim's system will be installed in neuroscience clinics, and new investments may be made in clinic service companies in the large US market. Nexstim Investments, LLC, Nexstim's



venture capital company, aims to expand Nexstim's network of partner clinics in the United States in collaboration with carefully selected leading experts in the field. We will continue to develop our cooperation model with experts, enabling the treatment of more patients in the United States with Nexstim's TMS technology. During the strategy period, we aim to increase the number of Nexstim systems and treatment sessions at our partner clinics.

Our third strategic objective for 2025 is to launch the new NBS 6 diagnostic system in our main markets, enabling ease of use and future add-on modules in the same system. The development and launch of a new product generation will continue to be an essential part of Nexstim's operations during the 2025–2028 strategy period. NBS 6 is a new combination system built on Nexstim's unique, clinically established technology, with a modular system concept that makes it easy to add new features to existing systems. Nexstim's NBS 6 system has FDA marketing and distribution approval for the treatment of major depression in the United States and is CE-approved in Europe for the treatment of major depression and chronic neuropathic pain. We will now continue to finalize the development of the system and progress regulatory approvals during 2025 so that, in line with our strategic objective, we will also have diagnostic applications launched in the key markets as part of the new NBS 6 system.

### ***Building future growth paths***

Our system clearly stands out from other TMS systems currently on the market, which do not have navigation features. In the future, the need for navigation functionality is likely to become even more important in technology, enabling more diverse treatment of brain disorders. This may open new markets for Nexstim in TMS treatments beyond severe depression and chronic neuropathic pain. The technological leadership, ease of use, and scalability of our product create an attractive foundation for growth through partnerships.

In January 2025, the company announced the start of joint development of the SinaptiStim® precision neuromodulation system for the treatment of Alzheimer's disease together with Sinaptica Therapeutics, Inc. ("Sinaptica"). The company announced that the planned delivery of the research system for the first validation testing, and future clinical trials was in March. Nexstim announced that it is developing the system according to Sinaptica's specifications, combining it with a high-resolution 64-channel electroencephalography (EEG) system from Bittium, which enables precision calibration of the therapy for each Alzheimer's patient. The new research system will be used in Sinaptica's upcoming clinical trials related to the treatment of Alzheimer's disease, with several studies planned to begin in 2025.

At the end of June 2025, the Company announced that it had signed an exclusivity agreement with Sinaptica Therapeutics, Inc. regarding the companies' planned collaboration in the field of Alzheimer's disease treatment. The signed agreement covers plans for 2025. The final agreement is expected to be drafted and signed before the end of the year. In June 2024, the Company announced that it had signed a letter of intent with Sinaptica regarding the development, manufacture, and supply of Sinaptica's patented precision neuromodulation system for the treatment of Alzheimer's disease and MCI (mild cognitive impairment). The system is based on Nexstim's NBS 6 medical TMS and neuronavigation systems and related software, including integrated EEG software. As part of the signed exclusive agreement, Sinaptica undertakes to order the research system it needs for clinical trials from Nexstim, and Nexstim will not commercialize its technology in the field of Alzheimer's disease independently or with partners other than Sinaptica. The agreed exclusivity is conditional upon payments of EUR 1.5 million in multiple installments to Nexstim during 2025. The planned partnership would be a global, 10-year exclusive arrangement. The financial structure of the partnership consists of a signing fee for the disclosed exclusivity rights, a milestone-based development project, and the sale of clinical and commercial system. The milestone-based project and purchases of clinical system are defined in more detail in the final agreements, which may be subject to change during negotiations. The long-term exclusive rights arrangement also depends on payments to be made by Sinaptica during 2025 and the signing of final agreements before the end of 2025.

### ***Building shareholder value while taking exceptional circumstances into account***

Despite the tense global political situation, our expectations for the rest of 2025 are positive in many ways. Our current business is heavily focused on the EU and the US, but with our new partners, we will continue to actively expand Nexstim's technology into the Asian market. Nexstim will continue its determined efforts to develop personalized and effective methods for the treatment and diagnosis of severe brain diseases and disorders. We strongly believe that our work will support long-term shareholder value growth in the form of increasingly strong competitive advantages, rapid



growth, and improved financial results.

## **Nexstim's business areas**

### **Diagnostics Business**

- Nexstim's NBS 5 system is the only CE-marked and FDA-cleared non-invasive solution for pre-surgical mapping of the motor cortex in brain cancer. Clinical data has been generated demonstrating the value of Nexstim's unique navigation system for pre-surgical mapping with regard to patient outcomes.
- The system allows surgeons to be better prepared and more aggressive with tumor resection, due to their confidence in the location of the motor and speech cortex because of pre-surgical mapping.
- More than 250 diagnostic systems have been sold to research universities and leading hospitals across the world.

### **Therapy Business**

- Nexstim's NBT<sup>®</sup> and NBS 6 systems are based on its unique navigated Transcranial Magnetic Stimulation (nTMS) technology, which allows for personalized, accurate, reproducible, and non-invasive brain stimulation.
- In May 2018, Nexstim launched its Navigated Brain Therapy (NBT<sup>®</sup>) system in the United States for the treatment of MDD, following FDA clearance in November 2017.
- Nexstim launched the NBS 6 system for therapy use in 2024. The NBS 6 is a new generation Nexstim system with a modular system concept that makes it easy to add new features to existing systems.
- Both NBT<sup>®</sup> and NBS 6 systems are CE marked for the treatment of major depression and chronic pain, and have FDA approval for the treatment of major depressive disorder (MDD).
- Active commercial installed base of 116 therapy systems across four continents (including both NBT<sup>®</sup> and NBS 6 systems and NBS systems with optional NBT<sup>®</sup> add-on software installed).

### **Research and Neuroscience Business**

- The core of the Research and Neuroscience business is the sale of Nexstim systems and support and development services to leading research hospitals and clinics, in order to support leading expert customers (key opinion leaders, KOLs) working in these institutions at the forefront of technological and clinical development.
- The international research community is particularly interested in developing therapies based on the stimulation of connections/neural networks between different areas of the brain. Nexstim's unique electric field neuronavigation has proven to be particularly useful and necessary in this regard.
- TMS-EEG diagnostics and treatment development based on this methodology are a growing area of interest in research. Here, too, neuronavigation and Nexstim's real-time EEG (electroencephalography) software are particularly useful and are attracting growing interest.

# Nexstim

## Financial review January 1 to June 30, 2025

### Operating result

EUR thousand	1-6/2025 6 months	1-6/2024 6 months	Change, %	1-12/2024 12 months
<b>Net sales</b>	<b>4,506.2</b>	<b>3,176.9</b>	<b>41.8 %</b>	<b>8,735.4</b>
<i>Net sales adjusted for currency exchange rates</i>	<i>4,523.3</i>	<i>3,174.7</i>	<i>42.5 %</i>	<i>8,709.6</i>
<i>Comparable net sales adjusted for non-recurring items*</i>	<i>4,306.2</i>	<i>3,176.9</i>	<i>35.5 %</i>	<i>8,735.4</i>
<i>Diagnostics</i>	<i>2,500.5</i>	<i>1,512.2</i>	<i>65.3 %</i>	<i>4,429.7</i>
System sales	1,733.8	942.2	84.0 %	3,149.8
Recurring net sales**	766.7	570.0	34.5 %	1,279.9
<i>Therapy</i>	<i>1,447.9</i>	<i>1,580.8</i>	<i>-8.4 %</i>	<i>3,978.5</i>
System sales	181.2	287.5	-37.0 %	1,505.2
Recurring net sales	1,266.6	1,293.3	-2.1 %	2,473.3
<i>Research and Neuroscience***</i>	<i>557.9</i>	<i>83.8</i>	<i>565.7 %</i>	<i>327.1</i>
System sales	294.4	0.0	100.0 %	135.8
Recurring net sales	63.5	83.8	-24.2 %	191.3
Licensing	200.0	0.0	100.0 %	0.0

\*The revenues for the first half of 2025 have been adjusted for the first EUR 0.2 million installment of the license fee under the Sinaptica exclusive agreement.

\*\*The distribution and development cooperation agreement signed with Brainlab AG includes a gross profit insurance of which EUR 121.1 thousand was recognized as recurring net sales in the first half of 2025 under the Diagnostics business.

\*\*\*The Research and Neuroscience business will be separated into its own business area in 2025. In previous years, revenue from the Research and Neuroscience business has been reported as part of either the Diagnostics or Therapy businesses, depending on its nature. The revenue distribution for the comparison periods has been adjusted to reflect the new presentation.

### Significant items in the operating result

Work performed for Nexstim's own purposes amounted to EUR 861.3 thousand (774.4) and consisted of capitalized development costs. The development costs capitalized during the review period are mainly related to the further development of the company's commercialized products.

Expenses related to materials and services totaled EUR -872.4 thousand (-573.8). The gross margin was 80.6% (81.9), and the adjusted comparable gross margin was 79.7% (81.9).

The company's operating expenses by function were as follows:

EUR thousand	1-6/2025 6 months	1-6/2024 6 months	Change, %	1-12/2024 12 months
Sales & Marketing*	2 003,9	1 739,2	15 %	3 551,4
Research & Development**	1 104,4	984,5	12 %	2 246,9
Administration***	1 151,0	1 120,9	3 %	2 333,3



# Nexstim

<b>Operating expenses total</b>	<b>4 259,3</b>	<b>3 844,7</b>	<b>11 %</b>	<b>8 131,5</b>
---------------------------------	----------------	----------------	-------------	----------------

\* Includes personnel and other business expenses for sales, marketing, customer support and logistics

\*\* Includes personnel and other business expenses for product development and clinical support

\*\*\* Includes personnel and other business expenses for administration, quality support and regulatory affairs

## ***Operating result***

The operating result was EUR -246.4 thousand (-864.2). The improvement of operating result was mainly due to the growth of net sales and sales margin.

## ***Financial income and expenses***

Net financial income and expenses amounted to EUR -87.6 thousand (-79.1). Financial expenses (-109.1) mainly consisted of interest payments on loans, exchange rate losses and payment transaction expenses. Financial income (21.4) mainly consisted of interest income and shares in the results of associated companies.

## ***Result for the period***

The result for the period was EUR -338.8 thousand (-948.1).

## **Financial position**

### ***Non-current assets***

The company's non-current assets were EUR 5,456.8 thousand (4,519.4). Intangible assets amounted to EUR 4,244.2 thousand (3,420.1), consisting mainly of capitalized development costs and intellectual property rights. Tangible assets amounted to EUR 298.4 thousand (403.8) and consisted mainly of NBT<sup>®</sup> systems used for business operations. Investments totaled EUR 914.3 thousand (695.5), consisting of strategic investments in the management service companies of US based partnership clinics.

### ***Current assets***

The company's current assets amounted to EUR 6,890.5 thousand (6,668.4). The change in current assets was mainly due to changes in inventories, trade receivables and cash.

### ***Total equity***

Consolidated shareholders' equity totaled EUR 3,179.3 thousand (1,867.7). The equity ratio increased to 31.9 % (28.7).

### ***Liabilities***

#### ***Non-current liabilities***

The company's non-current liabilities totaled EUR 3,651.2 thousand (4,857.2). Its non-current liabilities consist of interest-bearing long-term product development loans from Business Finland, a loan from Nordea and a loan from Finnvera. The loans do not include covenants.

#### ***Current liabilities***

The company's current liabilities totaled EUR 5,516.7 thousand (4,462.9). Its current liabilities mainly consist of product development loans from Business Finland, a loan from Nordea, a loan from Finnvera, prepayments received, trade payables, and accrued expenses.

### ***Financing and liquidity***

# Nexstim

Liquid assets, consisting of cash in hand and at bank, totaled EUR 2,662.7 thousand (3,032.1).

The company's net cash flow from operating activities during the review period was EUR 314.6 thousand (699.6). The change in cash flow from operating activities was mainly due to the improvement in the result for the review period, the reduction in short-term interest-free liabilities, and other adjustments.

Cash flow from investing activities in the review period was EUR -906.5 thousand (-944.4) which mainly consisted of capitalized development costs.

Cash flow from financing activities in the review period was EUR -541.9 thousand (1,813.5) and mainly consisted of long-term loan repayments.

## Organization and personnel

Nexstim's strategy is to recruit only employees who the company believes have the core competence and expertise to enable the company to operate efficiently. In line with this strategy, Nexstim has outsourced a part of its operations such as production.

The company is organized into the following global key processes:

- Growth: sales, marketing, customer support and operations;
- Enablers: research and development (R&D), clinical, quality approvals and regulatory clearances
- Support: administration, including Finance, Legal Affairs, IT and HR.

At the end of the review period on 30 June 2025, the Nexstim Group had 40 permanent employees. Nexstim Plc (the parent company) had 31 permanent employees on 30 June 2025. Between 1 January and 30 June 2025, the Nexstim Group had an average of 40 permanent employees (2024: 37).

## Strategy

### *Our mission*

We enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Our innovations create a possibility for a better life.

### *Our vision*

Through our technological know-how and superior services, we:

- Ensure the best possible treatments for our patients,
- deliver the greatest value for our customer hospitals, clinics and business partners,
- and long-term growth in shareholder value for our investors.

### *Our values*

- Science and clinical evidence
- Financial success
- Passion and commitment
- Ethics and responsibility

### *Key strategic objectives for 2025*

- Profitable growth: Increase net sales and improve operating result for the financial year while minimizing future capital requirements
- Strategic partnerships: Successfully supporting the long-term collaboration between Nexstim and Brainlab and expanding the network of other partners and clinics primarily in the US





- Technology leadership: Launching the new NBS 6 diagnostics system in key markets, enabling ease-of-use and future add-on modules in the same system

More information about the company's strategy is available on our website at <https://www.nexstim.com/about-nexstim/values-and-strategy>

## **Significant events from the review period**

### **Decisions of the Annual General Meeting**

March 27, 2025, the company announced the decisions of the Annual General Meeting as follows:

The Annual General Meeting approved the company's financial statements and consolidated financial statements for 2024 and decided that no dividend would be paid for the financial year 1 January–31 December 2024 and that the result for the financial year 1 January–31 December 2024 would be recorded in retained earnings account.

The Annual General Meeting decided to discharge the members of the Board of Directors and the CEO from liability for the financial year 1 January–31 December 2024.

The Annual General Meeting decided, in accordance with the proposal of the Nomination Committee, that:

- The number of members of the Board of Directors is confirmed as four (4).
- Tero Weckroth, Timo Hildén, Martin Forss, and Leena Niemistö are re-elected as members of the Board of Directors.
- In accordance with her consent, Leena Niemistö is elected as Chair of the Board of Directors.

In accordance with the proposal of the shareholders' Nomination Committee, the Annual General Meeting decided that the members of the Board of Directors elected at the Annual General Meeting shall be paid remuneration for the period ending at the close of the 2026 Annual General Meeting as follows:

- EUR 24,000 and 12,000 options for the Chair of the Board of Directors;
- EUR 12,000 and 8,500 options for the members of the Board of Directors
- No member of the Board of Directors serving on the Shareholders' Nomination Committee shall receive compensation for their work on the Shareholders' Nomination Committee.

A member of the Board of Directors is entitled to remuneration only for the period during which he or she serves as a member of the Board of Directors. In accordance with the company's practice, the monetary remuneration is paid in four installments.

The company will establish an option program for members of the board of directors, which will be priced 20 trading days after the date of the general meeting based on the VWAP of trading on the Helsinki list, with a subscription period from July 1, 2026, to December 15, 2031. The purpose of the option program is to commit participants to the company, align the goals of shareholders and participants, and thereby increase the value of the company. The target group for the commitment option program is members of the board of directors who are independent of the company. However, members of the target group do not need to be independent of the company's shareholders. Participants are recommended to hold the options paid as remuneration for as long as they serve as members of the Board of Directors.

In addition, it was decided that reasonable travel expenses will be reimbursed to members of the Board of Directors in accordance with the company's travel policy, upon presentation of receipts. This applies to both members of the Board of Directors and, where applicable, to members of the Board of Directors who also serve as members of the Shareholders' Nomination Committee.

The Annual General Meeting decided that PricewaterhouseCoopers Oy, a firm of authorized public accountants, which has appointed Tiina Puukkonen, APA, as the principal auditor, shall be elected as the company's auditor for the period ending at the close of the next Annual General Meeting. The proposed auditor has given his consent to the appointment. The General Meeting also decided that the auditor shall be paid a reasonable fee in accordance with a reasonable invoice approved by the company.



The General Meeting decided to authorize the Board of Directors to decide on (i) the issue of new shares and/or (ii) the transfer of treasury shares held by the company and/or (iii) the granting of special rights referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act on the following terms and conditions:

Right to shares:

New shares may be issued and the company's own shares may be transferred

- to the company's shareholders in proportion to their existing holdings in the company; or
- in a directed share issue, deviating from the shareholders' preemptive rights, if there is a compelling financial reason for the company to do so, such as using the shares as consideration in possible acquisitions or other arrangements related to the company's business operations or financing investments.

New shares may also be issued free of charge to the company itself. Paid and free share issues: New shares may be issued and treasury shares held by the company may be transferred either for consideration (paid share issue) or free of charge (free share issue). A directed share issue may only be free of charge if there is a particularly compelling financial reason for this, taking into account the interests of the company and all its shareholders. The Board of Directors is authorized to decide on the issuance of new shares and/or the transfer of treasury shares held by the company so that the total number of shares to be issued and/or transferred does not exceed 1,400,000, which corresponds to approximately 16.35 percent of all shares in the Company after the share issue, if new shares are issued, taking into account all registered shares in the Company.

The board of directors may grant special rights referred to in Chapter 10, Section 1 of the Limited Liability Companies Act, which entitle the holder to receive new shares or treasury shares held by the company in exchange for payment. Such rights may also be granted to a creditor of the company, provided that the rights are subject to a condition that the creditor's claim is used to offset the subscription price of the shares (convertible bond). The number of new shares subscribed for on the basis of special rights granted by the company and the number of transferable treasury shares held by the company may not exceed a total of 1,400,000, which amount is included in the maximum number mentioned above under "Maximum number of shares." The authorizations are valid until the next Annual General Meeting, starting from the decision of this Annual General Meeting.

The Annual General Meeting decided to authorize the Board of Directors to decide on (i) the issuance of new shares and/or (ii) the transfer of the Company's own shares held by the Company and/or (iii) the granting of special rights referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act on the following terms and conditions: The shares to be issued under the authorization shall be new shares of the Company or shares held by the Company. Based on and within the limits of the authorization, the Board of Directors may also decide on the issuance of option rights or other special rights referred to in Chapter 10 of the Finnish Limited Liability Companies Act alongside or instead of the issuance of shares. New shares may also be issued free of charge to the Company itself. New shares may be issued and the Company's own shares held by it may be transferred either against payment (paid share issue) or free of charge (free share issue). A directed share issue may only be free of charge if there is a particularly weighty financial reason for this, taking into account the interests of the Company and all its shareholders. The total number of shares issued under the authorization may not exceed 37,500 shares. This number represents approximately 0.52 percent of all shares in the Company after the share issue, if new shares are issued, taking into account all registered shares in the Company. The authorization is valid for five (5) years from the decision of the Annual General Meeting. The authorization may be used to implement long-term incentive programs for members of the Board of Directors, the Company's management, and personnel. The authorization may also be used to arrange incentives and pay the Board of Directors' remuneration.

## **Business**

January 15, 2025, the Company announced the start of joint development of the SinaptiStim® precision neuromodulation system for the treatment of Alzheimer's disease together with Sinaptica Therapeutics, Inc.

June 30, 2025 The company announced that it had signed an exclusive agreement with Sinaptica Therapeutics, Inc. regarding the companies' planned collaboration in the field of Alzheimer's disease treatment.

## **Employee stock options and other compensation programs**

# Nexstim

April 11, 2025 The company announced the subscription of shares with option rights for 2018 and 2020. A total of 21,412 new shares in the company were subscribed for with the 2018 and 2020 option rights between October 1, 2024, and March 31, 2025. The subscription price of EUR 46,924.70 for the subscriptions made with the option rights will be recorded in its entirety in the invested unrestricted equity fund. The company's share capital is EUR 80,000.00 after the subscription.

May 23, 2025, the company announced that on May 21, 2025, the company's board of directors decided to establish a new option 2025H option program for the members of the company's board of directors based on the authorization granted by the annual general meeting on March 27, 2025, and in accordance with the decisions of the general meeting. The maximum number of option rights to be issued under the 2025H program is 37,500, entitling their holders to subscribe for a total of up to 37,500 new shares or shares held by the company. The Board of Directors will decide whether to issue new shares or shares held by the company to subscribers. The subscription period for shares subscribed for with option rights 2025H is July 1, 2026–December 15, 2031.

For more information on material events during the reporting period, please visit the company's website: <https://www.nexstim.com/investors/releases>

## Significant events after the review period

The company has not had any major events after the review period.

## LARGEST SHAREHOLDERS

According to the register of shareholders maintained by Euroclear Finland Ltd, the holdings of Nexstim Plc's 20 largest shareholders on June 30, 2025 were as follows:

	Shareholder	Shares	Holding %
1.	Kaikaarhenni Oy	1,067,399	14.9 %
2.	Haapaniemi Ossi Antero	497,997	6.9 %
3.	Joensuun Kauppa Ja Kone Oy	435,689	6.1 %
4.	Skandinaviska Enskilda Banken Ab (Publ) Helsingin Sivukonttori*	296,901	4.1 %
5.	Syrjänen Eva Annika Elisabeth	160,966	2.2 %
6.	Citibank Europe Plc*	157,211	2.2 %
7.	Kalksten Properties Koy	154,124	2.1 %
8.	Wrcc Invest Oy	137,491	1.9 %
9.	Kalksten Finance Oy	113,104	1.6 %
10.	K22 Finance Oy	91,287	1.3 %
11.	Danske Bank A/S Helsinki Branch*	84,007	1.2 %
12.	Raiski Matti Juhani	78,132	1.1 %
13.	Schengen Investment Oy	71,460	1.0 %
14.	Kakkonen Kari Heikki Ilmari	70,649	1.0 %
15.	Niukkanen Pentti Juhani	64,497	0.9 %
16.	Ollikainen Pekka Antero	45,500	0.6 %
17.	Valkomedia Oy	44,842	0.6 %
18.	Ruponen Esa Juhani	43,877	0.6 %
19.	Kaukoranta Eero Onni	40,900	0.6 %
20.	Salmela Veijo Ensio	40,000	0.6 %

\*Nominee-registered shareholders



### **Publication of financial information**

The financial statements bulletin for the financial year that will end on December 31, 2025, will be published approximately on February 26, 2026 and the annual review will be published approximately on March 5, 2026.

### **Results briefing on August 15, 2025**

The company will hold two live webinars for the media, investors, and analysts on Friday, August 15, 2025. Mikko Karvinen, CEO, and Joonas Juokslahti, CFO, will present the company's financial and operational results, and will answer questions.

The first webinar will be held in Finnish at 10.30 am (EEST). The second webinar will be held in English at 3 pm (EEST).

### **Webinar details:**

To attend the webinars, please register via the links below. Registered participants will receive more information via email.

Webinar in Finnish on August 15, 2025, at 10:30 am (EEST): [Sign up here >>](#)

Webinar in English on August 15, 2025, at 3 pm (EEST): [Sign up here >>](#)

### **Basis of preparation of the half-year report**

Nexstim Plc's half-year report has been prepared in accordance with the Finnish Accounting Standards and presented in accordance with the rules of the First North marketplace. The financial information presented in the half-year report is unaudited. The figures presented have been subject to rounding adjustments.

# Nexstim

## CONSOLIDATED INCOME STATEMENT

Thousand euro	1 Jan. 2025 - 30 June 2025	1 Jan. 2024 - 30 June 2024	1 Jan. 2024 - 31 Dec. 2024
<b>NET SALES</b>	4,506.2	3,176.9	8,735.4
Capitalised fixed assets	861.3	774.4	1,477.9
Other operating income	4.8	0.7	74.1
Materials and services			
Materials			
Purchases during the review period	-953.8	-640.3	-1,584.4
Increase (+) or decrease (-) in inventories	94.3	69.8	-230.1
External services	-12.9	-3.3	-19.5
Total	-872.4	-573.8	-1,833.9
Personnel expenses			
Wages and salaries	-2,180.0	-1,942.5	-4,093.6
Social security expenses			
Pension expenses	-281.0	-242.2	-509.2
Other social security expenses	-130.8	-97.4	-181.6
Total	-2,591.7	-2,282.1	-4,784.5
Depreciation and amortization			
Depreciation and amortization according to plan	-487.0	-397.7	-857.3
Total	-487.0	-397.7	-857.3
Other operating expenses	-1,667.6	-1,562.6	-3,347.0
<b>OPERATING RESULT</b>	-246.4	-864.2	-535.4
Financial income and expenses	-87.6	-79.1	-351.9
<b>RESULT BEFORE TAXES</b>	-334.0	-943.3	-887.3
Income taxes	-4.7	-4.8	-5.0
<b>RESULT FOR THE PERIOD</b>	-338.8	-948.1	-892.3

# Nexstim

## CONSOLIDATED BALANCE SHEET

Thousand euro	30 June 2025	30 June 2024	31 Dec. 2024
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
Intangible assets			
Development expenditure	3,954.9	3,121.7	3,491.5
Intangible rights	284.6	291.4	276.2
Other intangible assets	4.7	7.1	5.5
<b>Total</b>	<b>4,244.2</b>	<b>3,420.1</b>	<b>3,773.2</b>
<b>Tangible assets</b>			
Machinery and equipment	298.4	403.8	358.4
<b>Total</b>	<b>298.4</b>	<b>403.8</b>	<b>358.4</b>
<b>Investments</b>			
Interests in associated companies	914.3	695.5	1,036.1
<b>Total</b>	<b>914.3</b>	<b>695.5</b>	<b>1,036.1</b>
<b>NON-CURRENT ASSETS TOTAL</b>	<b>5,456.8</b>	<b>4,519.4</b>	<b>5,167.7</b>
<b>CURRENT ASSETS</b>			
<b>Inventories</b>			
Raw materials and consumables	908.8	1,114.4	814.5
<b>Total</b>	<b>908.8</b>	<b>1,114.4</b>	<b>814.5</b>
<b>Receivables</b>			
Trade receivables	2,396.3	1,920.1	3,907.3
Receivables from associated companies	0.5	0.0	0.0
Prepayments and accrued income	689.5	417.7	352.1
Other receivables	232.6	184.1	96.6
<b>Total</b>	<b>3,318.9</b>	<b>2,521.9</b>	<b>4,356.0</b>
Cash in hand and at banks	2,662.7	3,032.1	3,864.4
<b>CURRENT ASSETS TOTAL</b>	<b>6,890.5</b>	<b>6,668.4</b>	<b>9,034.9</b>
<b>ASSETS TOTAL</b>	<b>12,347.3</b>	<b>11,187.8</b>	<b>14,202.7</b>



# Nexstim

Thousand euro	30 June 2025	30 June 2024	31 Dec. 2024
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Share capital	80.0	80.0	80.0
Reserve for invested unrestricted equity	56,903.8	55,042.3	56,856.9
Retained earnings	-53,465.7	-52,306.5	-52,344.7
Result for the period	-338.8	-948.1	-892.3
<b>TOTAL EQUITY</b>	<b>3,179.3</b>	<b>1,867.7</b>	<b>3,699.9</b>
<b>LIABILITIES</b>			
<b>NON-CURRENT LIABILITIES</b>			
Other interest-bearing loans	3,651.2	4,857.2	4,240.1
<b>Total</b>	<b>3,651.2</b>	<b>4,857.2</b>	<b>4,240.1</b>
<b>CURRENT LIABILITIES</b>			
Loans from financial institutions	1,122.6	1,453.8	1,122.6
Prepayments received	2,376.8	1,275.5	2,335.5
Trade payables	807.1	591.6	1,250.0
Other liabilities	179.1	223.8	300.9
Accrued expenses	1,031.2	918.3	1,253.7
<b>Total</b>	<b>5,516.7</b>	<b>4,462.9</b>	<b>6,262.7</b>
<b>TOTAL LIABILITIES</b>	<b>9,168.0</b>	<b>9,320.1</b>	<b>10,502.8</b>
<b>EQUITY AND LIABILITIES TOTAL</b>	<b>12,347.3</b>	<b>11,187.8</b>	<b>14,202.7</b>

## CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY

Thousand euro	Share capital	Reserve for invested unrestricted equity	Retained earnings (losses)	Total equity
<b>Equity at 31 December 2024</b>	80.0	56,856.9	-53,237.1	3,699.8
Issue of shares		46.9		46.9
Result for the period			-338.8	-338.8
Translation difference			-228.6	-228.6
<b>Equity at 30 June 2025</b>	80.0	56,903.8	-53,804.5	3,179.3

Thousand euro	Share capital	Reserve for invested unrestricted equity	Retained earnings (losses)	Total equity
<b>Equity at 31 December 2023</b>	80.0	55,042.3	-52,286.0	2,836.3
Issue of shares		1,814.6		1,814.6
Result for the period			-892.3	-892.3
Translation difference			-58.8	-58.8
<b>Equity at 31 December 2024</b>	80.0	56,856.9	-53,237.1	3,699.8

Thousand euro	Share capital	Reserve for invested unrestricted equity	Retained earnings (losses)	Total equity
<b>Equity at 31 December 2023</b>	80.0	55,042.3	-52,286.0	2,836.3
Issue of shares				0.0
Result for the period			-948.1	-948.1
Translation difference			-20.5	-20.5
<b>Equity at 30 June 2024</b>	80.0	55,042.3	-53,254.6	1,867.7

## CONSOLIDATED CASH FLOW STATEMENT

Thousand euro	1 Jan. 2025 - 30 June 2025	1 Jan. 2024 - 30 June 2024	1 Jan. 2024 - 31 Dec. 2024
<b>Cash flow from operating activities</b>			
Result for the period	-334.0	-943.3	-887.3
Adjustments:			
Depreciation and amortization according to plan	487.0	397.7	857.3
Other income and expenses not related to payment	0.0	0.0	0.0
Share of the profit of associates	-9.3	2.9	-26.6
Other adjustments (income -/ expense +)	644.4	-90.2	-205.5
Financial income and expenses	96.9	76.1	378.5
<b>Cash flow before change in working capital</b>	<b>885.0</b>	<b>-556.8</b>	<b>116.5</b>
<b>Change in working capital:</b>			
Increase (-) or decrease (+) in current receivables	852.2	950.0	-823.4
Increase (-) or decrease (+) in inventories	-126.8	-46.5	260.2
Increase (-) or decrease (+) in long-term receivables	0.0	0.0	0.0
Increase (+) or decrease (-) in current interest-free payables	-1,194.2	371.9	2,455.4
<b>Cash flows from operations before financial items and taxes</b>	<b>416.2</b>	<b>718.7</b>	<b>2,008.8</b>
Interest and other financial expenses paid	-109.1	-82.8	-230.7
Interest received on operating activities	12.2	68.5	107.9
Direct taxes paid	-4.7	-4.8	-5.0
<b>Cash flow from operating activities (A)</b>	<b>314.6</b>	<b>699.6</b>	<b>1,881.0</b>
<b>Cash flow from investing activities</b>			
Investments in intangible and tangible assets	-920.3	-944.4	-1,705.6
Investoinnit muihin sijoituksiin	0.0	0.0	-277.2
Proceeds from disposal of other investments	13.7	0.0	0.0
<b>Cash flow from investing activities (B)</b>	<b>-906.5</b>	<b>-944.4</b>	<b>-1,982.8</b>
<b>Cash flow from financing activities</b>			
Share issue	46.9	0.0	1,814.6
Drawing (+) or repayment of short-term loans (-)	0.0	622.2	0.0
Drawing (+) or repayment of long-term loans (-)	-588.8	1,253.1	927.1
Maksetut korot ja maksut rahoituskuluista	0.0	-61.8	-255.7
<b>Cash flow from financing activities (C)</b>	<b>-541.9</b>	<b>1,813.5</b>	<b>2,486.0</b>
<b>Change in cash in hand and at banks</b>	<b>-1,133.9</b>	<b>1,568.7</b>	<b>2,384.2</b>
<b>Cash in hand and at bank at the beginning of the period</b>	<b>3,864.4</b>	<b>1,454.6</b>	<b>1,454.6</b>
<b>Valuuttakurssimuutosten vaikutus</b>	<b>-67.8</b>	<b>8.9</b>	<b>25.6</b>
<b>Cash in hand and at bank at the end of the period</b>	<b>2,662.7</b>	<b>3,032.1</b>	<b>3,864.4</b>

## MATERIAL TRANSACTIONS WITH RELATED PARTIES

Nexstim's related parties include its subsidiaries, the members of its Board of Directors, the CEO, and the members of its Management Team, as well as shareholders who exercise considerable influence in the company. The company's related parties also include close family members of such persons, as well as entities in which such persons have a controlling interest. The company did not have any material transactions with related parties during the review period.

## CONTINGENT LIABILITIES

Thousand euro	30.6.2025	30.6.2024	31.12.2024
<b>Rental guarantees</b>			
Rental deposit account	16,3	16,3	16,3
<b>Leasing liabilities</b>			
Due within the next financial year	88,4	74,1	74,5
Due later	668,1	4,2	4,2
<b>Leasing liabilities</b>			
Due within the next financial year	2,8	2,6	4,0
Due later	-	-	-

## CALCULATION OF KEY FIGURES

Gross margin	Net sales - Materials and services
Gross margin-%	Gross margin / Net sales
Adjusted comparable gross margin	(Net sales - extraordinary items) - Materials and services
Adjusted comparable gross margin-%	Adjusted comparable gross margin / Net sales
EBITDA	Operating result + Depreciation and amortization
Earnings per share	Result for the review period / Average number of shares
Diluted earnings per share	Result for the review period / Diluted average number of shares
Equity ratio (%)	100 * (Equity + Voluntary reserves) / (Adjusted balance sheet total - Advance payments based on work performed)

Helsinki, August 15, 2025

Nexstim Plc  
Board of Directors

Further information is available on the website [www.nexstim.com](http://www.nexstim.com) or by contacting:

**Mikko Karvinen**, CEO  
+358 50 326 4101



mikko.karvinen@nexstim.com

The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

Distribution:  
Nasdaq Helsinki  
Key media outlets

#### **About Nexstim Plc**

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit [www.nexstim.com](http://www.nexstim.com)